First CRISPR therapies for blood disorders approved in 2023 will rank among world's most expensive drugs, costing $3 million per treatment due to complex manufacturing and administration requirements. Current pharmaceutical development system designed for profitable mass-market drugs cannot economically serve rare disease patients, despite having the technology to cure them within 3-5 years.
El País
· Feb 03, 2023
· health
· 7 min de leitura
High
Apuração: Verificado
CRISPR's Promise Meets Market Reality: First Gene-Editing Drugs to Cost $3M
Approximately 300 million people worldwide suffer from rare genetic diseases; many will remain untreated despite available CRISPR technology due to prohibitive costs and lack of market incentives.
◉
Economy & Finance
963 artigos relacionados
Wall Street's AI Rally Echoes 1987 Crash Warning Signs
OkDiario · 99% correspondência
Wall Street surges on signs of economic cooling, Fed rate-hike pause l…
infobae · 99% correspondência
Asian stocks fall as Treasury yields hold gains amid inflation concern…
Bloomberg Línea · 99% correspondência
Inflation Surge Signals Sell for Stock Market Investors as Macro Risks…
Bloomberg Línea · 99% correspondência
Wall Street hits records ahead of Fed rate cut decision
Diario Las Américas · 99% correspondência
Cobertura Relacionada
El País · Aug 19
Inflación, déficit y auge de la IA disparan los intereses de bonos a máximos de dos décadas
Los inversores exigen mayor rentabilidad para prestar a largo plazo ante inflación, déficits públicos elevados y compete…
Bloomberg Línea · Aug 19 Bolsas asiáticas se desploman por venta de semiconductores y alza de rendimientosLas bolsas asiáticas retrocedieron más del 1% mientras las acciones de semiconductores se desplomaron y los elevados ren…
Google News · Aug 18 Phantom Blade Zero: el RPG wuxia que revoluciona los combates con Donnie YenPhantom Blade Zero presenta su nuevo gameplay de combate wuxia con consultoría del actor Donnie Yen, aprovechando las fu…
Bloomberg Línea · Aug 18 Monedas emergentes se fortalecen por debilidad del dólar y mayor apetito por riesgoEl índice de monedas emergentes de MSCI subió 0,2% mientras el dólar se debilitó por tercer día consecutivo, impulsado p…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
CRISPR gene-editing drugs costing €3M per patient will create global health inequities, limiting treatment access to wealthy nations and exacerbating healthcare disparities affecting 300M people with rare genetic diseases.
Escalation Risk
moderate
Confidence
HIGH
United States
European Union
Global South
Middle-income countries
Low-income countries
Wealthy nations and pharmaceutical corporations gain monopolistic control over life-saving genetic therapies, while developing nations face exclusion. This reinforces existing healthcare inequalities and shifts biomedical power toward high-income economies and Big Pharma, potentially triggering international pressure for price regulation and compulsory licensing.
Similar to early antiretroviral HIV/AIDS drug pricing (1990s-2000s), where patent protections and high costs restricted access in developing nations until generic competition and international advocacy forced price reductions. CRISPR pricing may trigger comparable geopolitical tensions over drug accessibility and intellectual property.
Lente Econômica
📈
First CRISPR gene-editing drugs priced at €3M per patient create significant access barriers despite technological capability to treat 300M people with rare genetic diseases globally.
Market Signal
mixed
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Health Insurance
Public Health Systems
Medical Devices
Patients with rare genetic diseases face severe affordability barriers despite curative potential. Most households and healthcare systems cannot absorb €3M treatment costs, limiting access to wealthy populations and well-funded healthcare systems. Creates two-tier healthcare outcomes based on economic status.
Governments likely to implement price regulation mechanisms, negotiate bulk purchasing agreements, or mandate insurance coverage frameworks. May trigger patent reform discussions, compulsory licensing debates, and increased public funding for gene therapy research. EU and national health authorities may establish reimbursement criteria and cost-effectiveness thresholds.